Roquette Frères, Ligand Pharmaceuticals Incorporated, and Wacker Chemie AG are Dominating the Global Cyclodextrins In Pharma Market in 2019

Cyclodextrins In Pharma Market is expected to grow with the CAGR of 3.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/global-cyclodextrins-in-pharma-market

Cyclodextrins in pharma market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario. 

The major players dealing in global cyclodextrins in pharma market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In September 2017, Roquette Frères opened a fermentation laboratory for invention in a biotech solution in the healthcare market. This has helped to strengthen the portfolio as well as the image of the company in the market.

Roquette Frères is the dominating player in cyclodextrins in pharma market. The other key players existing in the market includes Cambrex Corporation, Cayman Chemical, Wellona Pharma, Wacker Chemie AG, Cyclolab, Tocopharm Co. Limited, Merck KGaA, Midas Pharma GmbH, Ligand Pharmaceuticals Incorporated, Cyclo Therapeutics, Inc., Zibo Qianhui biological technology co., ltd, and Xi'an Deli Biochemical Industry Co., Ltd among others.

Cyclodextrins In Pharma Market, By DevelopmentsRoquette Frères

Roquette Frères headquarter is in Lestrem, France, was founded in 1933. Roquette Frères is one of the main leaders in plant-based plant substances and is the largest producer of pharmaceutical excipients. They offer the best natural ingredients in the food, nutrition and health markets. The company has wide product portfolio such as bio pharma, pharma & nutraceuticals, cosmetics, food & nutrition, animal nutrition, industrial markets, nutralys plant protein in which pharma & nutraceuticals is the market focused category.

  • In December 2018, Roquette Frères partnered with Thermo Fisher Scientific Inc. to distribute its drugs in the United States and Canada. This step has been taken to support the great growth potential for both world leaders.

The company has wide presence across Europe, North America, Latin America, Asia Pacific. The company also has various subsidiary companies such as Roquette Korea Ltd. (South Korea), Roquette Laisa España, SA (Spain), Roquette CH (SwitzerlandRoquette Netherlands B.V (Netherlands), Roquette UK Ltd.,(U.K), among others.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated headquartered in California, U.S. was founded in 1987. The company focuses on developing or acquiring technology that helps pharmaceutical companies discover and develop drugs. The company has wide product portfolio including omniab, captisol, vernalis design platform, LTP technology, suretechnology platform in which captisol is the market focused product.

  • In November 2019, Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of the Captisol Active (Iohexol) program at ASN Kidney Week 2019 in Washington, DC. The CE-Iohexol program was launched in January 2018 to develop Captisol-active, the next diagnostic imaging agent with reduced risk of nephrotoxicity. The study reached the primary endpoint of biological-biological equivalence between CE-Iohexol solution for injection and Iohexol injection (Omnipaque after) reference after intravenous (IV) administration in healthy adults. This conference made the company more popular with its pharmaceutical companies.

The company has wide presence across North America, South America, Europe, Middle East and Africa and Asia-Pacific. The company also has various subsidiary companies such as CyDex Pharmaceuticals, Inc. (U.S.), Metabasis Therapeutics, Inc (U.S.), Vernalis Research (U.K), Neurogen Corporation (U.S.), Ligand Holdings Uk Ltd (U.K) among others.

Wacker Chemie AG

Wacker Chemie AG headquartered in Munich, Germany was founded in 1914. Wacker is a global company specializing in chemical products. Wacker has high demand in the construction and automotive industries. The company is engaged in providing wide range of product categories such as acetyls, dispersable polymer powders, polymer dispersions, pyrogenic silica, silicone fluids and emulsions, silicone sealants, amino acids, fine chemicals, polymer resins, silane modified polymers, silicone resins, cyclodextrin & complexes, hydroxytyrosols, polysilicon, silanes, siloxanes and silicates, silicone resins, silicone rubber, silicone sealants in which cyclodextrin & complexes is the market focused product categories.

  • In November 2018, Wacker Chemie AG acquired pharmaceutical company SynCo Bio Partners B.V. and renamed as Wacker Biotech B.V. This site has been used for the manufacture of medicines, live microbial products and vaccines. These acquisitions have helped the company increase the production of cyclodextrin for drug use and thus increase its market share.

The company is present in North America, South America, Europe, Middle East and Africa and Asia-Pacific. The company has several owned subsidiaries involving Wacker Polysilicon North America, LLC (U.S.), Wacker Química do Brasil Ltda. (Brazil), Wacker Chemicals Korea Inc. (South Korea), Wacker Chemicals East Asia Ltd. (Japan), Wacker Chemicals (China) Company Ltd. (China) among more.